CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”) ...

Alcon Inc.'s acquisition of LENSAR, Inc. remains pending, with an FTC antitrust review likely delaying the closing. Learn ...

Please provide your email address to receive an email when new articles are posted on . Rumors swirled around the exhibit floor and coursed through gatherings of dry eye disease docs who attended the ...

GENEVA, March 26, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority ...

Narrow-moat Alcon discussed current projects and initiatives, pipeline progression, and long-term financial goals in its 2025 Capital Markets Day. After digesting the performance of each business unit ...

Please provide your email address to receive an email when new articles are posted on . Six months after its merger with Novartis was finalized, Alcon is poised to expand its global eye care market in ...

Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the ...

Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO ...